We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Democrats and Advocacy Groups Press HHS to Assert ‘March-in’ Rights Over Pricy Prostate Cancer Drug Xtandi
Democrats and Advocacy Groups Press HHS to Assert ‘March-in’ Rights Over Pricy Prostate Cancer Drug Xtandi
Democrats in the U.S. House of Representatives and eight advocacy groups are pressing Department of Health and Human Services (HHS) head Xavier Becerra to use either “march-in” or government use rights for the prostate cancer drug Xtandi, which is marketed by Pfizer and Japanese company Astellas but was developed using grant funding from the U.S. Army and the National Institutes of Health (NIH).